Literature DB >> 19065715

Chemoprevention in Barrett's esophagus.

Sumera Ilyas1, Cathrine J DeMars, Navtej S Buttar.   

Abstract

Barrett's metaplasia-associated esophageal adenocarcinoma is one of the most rapidly increasing cancers in Western countries. Whereas early detection remains the cornerstone of prevention, chemoprevention is emerging as a complementary strategy. Carcinogenesis in Barrett's mucosa is a multistep process in which cellular growth becomes progressively dysregulated. Fortunately, the process of carcinogenesis is a protracted one, which provides ample opportunity for intervention. In this review, we will discuss various potential chemoprevention targets and rationale behind their use to prevent Barrett's related esophageal adenocarcinoma. We will also critically appraise the emerging preclinical and clinical literature regarding prevention of neoplasia in Barrett's esophagus.

Entities:  

Mesh:

Year:  2007        PMID: 19065715     DOI: 10.1007/s12029-007-9006-7

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  75 in total

1.  Cytochromes P450 are expressed in proliferating cells in Barrett's metaplasia.

Authors:  S J Hughes; M A Morse; C M Weghorst; H Kim; P B Watkins; F P Guengerich; M B Orringer; D G Beer
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

2.  Acid suppression and adenocarcinoma of the esophagus: cause or cure?

Authors:  Thomas G Schell
Journal:  Am J Gastroenterol       Date:  2004-10       Impact factor: 10.864

3.  Barrett's esophagus: does the incidence of adenocarcinoma matter?

Authors:  A J Cameron
Journal:  Am J Gastroenterol       Date:  1997-02       Impact factor: 10.864

4.  Acid increases MAPK-mediated proliferation in Barrett's esophageal adenocarcinoma cells via intracellular acidification through a Cl-/HCO3- exchanger.

Authors:  George A Sarosi; Kshama Jaiswal; Emily Herndon; Christie Lopez-Guzman; Stuart J Spechler; Rhonda F Souza
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-08-04       Impact factor: 4.052

5.  Differential expression of retinoic acid receptors and p53 protein in normal, premalignant, and malignant esophageal tissues.

Authors:  W Zhang; A Rashid; H Wu; X C Xu
Journal:  J Cancer Res Clin Oncol       Date:  2001-04       Impact factor: 4.553

6.  Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus.

Authors:  M K Hong; W B Laskin; B E Herman; M H Johnston; J J Vargo; S M Steinberg; C J Allegra; P G Johnston
Journal:  Cancer       Date:  1995-01-15       Impact factor: 6.860

7.  Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia.

Authors:  W H Chow; W J Blot; T L Vaughan; H A Risch; M D Gammon; J L Stanford; R Dubrow; J B Schoenberg; S T Mayne; D C Farrow; H Ahsan; A B West; H Rotterdam; S Niwa; J F Fraumeni
Journal:  J Natl Cancer Inst       Date:  1998-01-21       Impact factor: 13.506

8.  Bile salts induce or blunt cell proliferation in Barrett's esophagus in an acid-dependent fashion.

Authors:  B S Kaur; R Ouatu-Lascar; M B Omary; G Triadafilopoulos
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2000-06       Impact factor: 4.052

9.  Association between body mass and adenocarcinoma of the esophagus and gastric cardia.

Authors:  J Lagergren; R Bergström; O Nyrén
Journal:  Ann Intern Med       Date:  1999-06-01       Impact factor: 25.391

Review 10.  Reflux, Barrett's oesophagus and adenocarcinoma: burning questions.

Authors:  Christopher P Wild; Laura J Hardie
Journal:  Nat Rev Cancer       Date:  2003-09       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.